ArticleFrontiers in pharmacology2026
Crocin protects against smoke-induced chronic obstructive pulmonary disease by regulating AKT1.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic obstructive pulmonary disease (COPD) is an inflammatory airway disorder characterized by persistent airflow limitation and pathological features such as airway remodeling. Identifying molecular targets involved in airway epithelial dysfunction is crucial for developing COPD therapies. Crocin, a carotenoid glycoside from saffron ( Methods: We first employed predictive strategies, including network analysis, to identify common targets of crocin and COPD. Protein-protein interaction (PPI) networks were constructed, and core targets were screened via topology analysis. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were performed to predict signaling pathways. Molecular docking and dynamics simulations were then used to assess the binding potential between crocin and the core targets. Finally, the function of crocin against COPD was evaluated using the Cellular Thermal Shift Assay (CETSA) Results: Network analysis predicted 243 common targets, from which 48 candidate targets were identified. GO and KEGG enrichment analyses suggested the PI3K-AKT signaling pathway as a potentially key mechanism. Among the top-ranked core targets, molecular docking indicated favorable binding energies between crocin and proteins such as ALB and AKT1, a finding further corroborated by molecular dynamics simulations. Subsequent CETSA suggested a direct interaction between crocin and AKT1. Conclusion: These findings support the therapeutic potential of crocin in COPD through its anti-inflammatory activity and regulation of AKT1. Despite potential PAINS properties, the consistency across network,
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.